MAP2K7 and melanoma: To date, precision therapies targeting the BRAF/MEK/ERK pathway, including BRAF inhibitor (BRAFi) monotherapy using vemurafenib (VMF) and dabrafenib and combination therapy using dabrafenib and the MEKi trametinib, have been developed and have led to great advances in malignant melanoma therapy.2